Comparative Pharmacology
Head-to-head clinical analysis: XERAVA versus XIMINO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: XERAVA versus XIMINO.
XERAVA vs XIMINO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Eravacycline is a tetracycline-class antibacterial that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from attaching to the A-site. It exhibits activity against a broad range of Gram-positive, Gram-negative, and anaerobic bacteria, including many tetracycline-resistant strains due to modifications circumventing common resistance mechanisms.
XIMINO is a tetracycline-class antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
200 mg intravenously over 60 minutes every 12 hours
400 mg orally twice daily with food for 7 days.
None Documented
None Documented
Terminal elimination half-life is approximately 42 hours (range 30-60 hours) in healthy subjects; prolonged in elderly patients and those with severe hepatic impairment.
Terminal elimination half-life: 8 hours (range 6-10 hours) in healthy adults; prolonged to 15-20 hours in severe renal impairment (CrCl <30 mL/min).
Fecal (approximately 80-90% as unchanged drug); renal (less than 1% as unchanged drug).
Renal: 70% as unchanged drug; biliary/fecal: 20% as metabolites and unchanged drug; 10% metabolized via hepatic CYP3A4.
Category C
Category C
Antibiotic
Antibiotic